SLC25A10 and urinary bladder cancer: Although curtailing the expression of ABCC5, ABCA8, ABCC10, ABCB10, ABCG1, ATP7B, ABCG2, and the mitochondrial SLC25A10 has enhanced cisplatin’s susceptibility and response in various cancer types, including lung and liver cancers, further research should be directed at investigating their role in platinum-receiving urinary bladder cancer patients.